Detail

Study ID: Saint Lukes 1245.129 EMBRACE HF Trial

Title:

Empagliflozin Impact on Hemodynamics in Patients With Diabetes and Heart Failure (EMBRACE-HF)” among patients with type 2 diabetes and heart failure that have a CardioMEMs device in place

Description:
Title: EMpagliflozin evaluation By measuRing ImpAct on HemodynamiCs in PatiEnts with Heart Failure (EMBRACE-HF) Description: The purpose of this study is to find out if empagliflozin would be effective in reducing pressure in the pulmonary artery (the artery that directs blood out of the heart to the lungs) and improve the blood tests and symptoms related to heart failure. 4 Key Inclusion/Exclusion Criteria including Age Range If Applicable: Participants must be at least 18 years of age, have heart failure (inability of the heart to pump blood with normal efficiency) and also have an implantable pulmonary artery pressure sensor (CardioMEMs) which was inserted to help in the management of their heart failure.
Location:
Sioux Falls Region
Principal Investigator:
Orvar Jonsson, MD
Disease:
Heart
Stage:
Unknown
Status:
Active - Open to Accrual